Management of patients with early-stage triple-negative breast cancer following pembrolizumab-based neoadjuvant therapy: What are the evidences?-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Management of patients with early-stage triple-negative breast cancer following pembrolizumab-based neoadjuvant therapy: What are the evidences?

Published:2022-11 Issue: Volume:110 Page:102459
ISSN:0305-7372
Container-title:Cancer Treatment Reviews
language:en
Short-container-title:Cancer Treatment Reviews

Author:

Bonadio Renata Colombo,Tarantino Paolo,Testa Laura,Punie Kevin,Pernas Sonia,Barrios Carlos,Curigliano Giuseppe,Tolaney Sara M.,Barroso-Sousa Romualdo

Publisher

Elsevier BV

Subject

Radiology, Nuclear Medicine and imaging,Oncology,General Medicine

Reference59 articles.

1. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer;Liedtke;J Clin Oncol,2008

2. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis;Cortazar;Lancet,2014

3. Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy;Masuda;N Engl J Med,2017

4. Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer;Schmid;N Engl J Med,2022

5. Adjuvant Olaparib for Patients with BRCA1 - or BRCA2 -Mutated Breast Cancer;Tutt;N Engl J Med,2021

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Dose dense versus 3 weekly AC during neoadjuvant chemoimmunotherapy for triple negative breast cancer;npj Breast Cancer;2024-08-14

2. Shifting Paradigms in TNBC Treatment: Emerging Alternatives to Capecitabine in the Post-Neoadjuvant Setting;Current Oncology;2024-06-30

3. Navigating the complexity of post‐NAT therapy in breast cancer: The role of ctDNA testing;Journal of Surgical Oncology;2024-04-23

4. Post(neo)adjuvante Therapiekonzepte – Möglichkeiten der Individualisierung;Die Gynäkologie;2024-04-18

5. Current usage of pembrolizumab in triple negative breast cancer (TNBC);Expert Review of Anticancer Therapy;2024-04-16

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3